Ani Pharmaceuticals Inc. Stock
€62.50
Your prediction
Ani Pharmaceuticals Inc. Stock
Pros and Cons of Ani Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Ani Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ani Pharmaceuticals Inc. | -0.790% | -0.794% | 2.459% | 79.598% | 25.502% | 133.209% | 1.958% |
| Ardelyx Inc. | 0.100% | -7.414% | -16.973% | 36.533% | 6.298% | -15.255% | - |
| Salarius Pharmaceuticals Inc. | 0.930% | 6.468% | -31.520% | -69.209% | -22.883% | -98.226% | -99.994% |
| Evolus Inc | -2.630% | -5.882% | -12.500% | 43.590% | 19.786% | 18.519% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The quarterly financials of ANI Pharma (BPAX) appear to show a mixed picture. On the one hand, the company has experienced growth in total revenues, while also maintaining relatively stable operational expenses. On the other hand, BPAX has experienced a net loss in the recent quarter, giving room for potential concern. The following analysis will delve deeper into the pros and cons of ANI Pharma's financials.
Total assets have increased: The company's balance sheet shows a steady rise in total assets over the years, indicating growth and expansion. The increase in assets is primarily due to a surge in intangible assets and an increase in total current assets.
Rise in total revenue and gross profit: ANI Pharma has witnessed a growing trend in its quarterly total revenue and gross profit. This could signify stronger demand for their products and services or a successful implementation of growth strategies.